SVB Leerink restated their outperform rating on shares of Genocea Biosciences (NASDAQ:GNCA) in a report issued on Sunday, AnalystRatings.com reports. SVB Leerink currently has a $5.00 price objective on the biotechnology company’s stock.
Other equities analysts have also issued reports about the stock. Zacks Investment Research raised shares of Genocea Biosciences from a sell rating to a hold rating in a report on Wednesday, July 1st. Needham & Company LLC restated a buy rating and issued a $10.00 price target on shares of Genocea Biosciences in a research note on Tuesday, May 12th. Finally, HC Wainwright restated a buy rating and issued a $32.00 price target on shares of Genocea Biosciences in a research note on Tuesday, June 23rd. One investment analyst has rated the stock with a hold rating and four have assigned a buy rating to the stock. The company has an average rating of Buy and an average price target of $12.31.
GNCA stock opened at $2.13 on Friday. The company has a quick ratio of 1.98, a current ratio of 1.98 and a debt-to-equity ratio of 1.28. Genocea Biosciences has a 12 month low of $1.10 and a 12 month high of $3.94. The firm has a market cap of $59.15 million, a P/E ratio of -1.42 and a beta of 2.35. The company’s 50-day moving average price is $2.46 and its two-hundred day moving average price is $2.17.
Several institutional investors and hedge funds have recently bought and sold shares of GNCA. Renaissance Technologies LLC boosted its stake in shares of Genocea Biosciences by 37.4% in the 4th quarter. Renaissance Technologies LLC now owns 279,511 shares of the biotechnology company’s stock valued at $579,000 after purchasing an additional 76,149 shares in the last quarter. Oxford Asset Management LLP acquired a new stake in Genocea Biosciences during the 4th quarter worth approximately $27,000. FNY Investment Advisers LLC boosted its position in Genocea Biosciences by 9.1% during the 1st quarter. FNY Investment Advisers LLC now owns 300,000 shares of the biotechnology company’s stock worth $516,000 after buying an additional 25,000 shares during the period. NEA Management Company LLC acquired a new stake in Genocea Biosciences during the 1st quarter worth approximately $12,428,000. Finally, Bank of New York Mellon Corp acquired a new stake in Genocea Biosciences during the 1st quarter worth approximately $35,000. Institutional investors own 50.27% of the company’s stock.
About Genocea Biosciences
Genocea Biosciences, Inc, a biopharmaceutical company, discovers and develops novel cancer vaccines. The company uses its proprietary discovery platform, ATLAS, to recall a patient's pre-existing CD4+ and CD8+ T cell immune responses to tumor to identify antigens for inclusion in vaccines that are designed to act through T cell (or cellular) immune responses.
See Also: Basic Economics
Receive News & Ratings for Genocea Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Genocea Biosciences and related companies with MarketBeat.com's FREE daily email newsletter.